{"id":36716,"date":"2025-07-04T17:10:05","date_gmt":"2025-07-04T09:10:05","guid":{"rendered":"https:\/\/flcube.com\/?p=36716"},"modified":"2025-07-04T17:10:06","modified_gmt":"2025-07-04T09:10:06","slug":"msds-winrevair-accepted-for-priority-review-by-fda-for-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36716","title":{"rendered":"MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension"},"content":{"rendered":"\n

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK<\/a>) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.<\/p>\n\n\n\n

Phase III ZENITH Study Results<\/strong>
The filing leveraged results from the Phase III ZENITH study, a global, double-blind, placebo-controlled trial. The study evaluated Winrevair as add-on therapy to maximal tolerated background PAH treatment in adults with WHO FC III\/IV PAH. It used a novel primary endpoint of time to first occurrence of all-cause death, lung transplant, or PAH-related hospitalization lasting \u226524 hours.<\/p>\n\n\n\n

Trial Significance and Outcomes<\/strong>
ZENITH is the first PAH Phase III study with a primary endpoint exclusively comprising major morbidity\/mortality events. It is also the first PAH Phase III trial concluded early by an independent data monitoring committee due to overwhelming efficacy. Results showed Winrevair achieved a 76% risk reduction in the composite endpoint versus placebo, with early clinical benefits that increased over time and a safety profile consistent with previous studies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food…<\/p>\n","protected":false},"author":1,"featured_media":36717,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2675,176,903,80,24],"class_list":["post-36716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-priority-reviews","tag-rare-orphan-disease-drugs"],"yoast_head":"\nMSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36716\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36716\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T09:10:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T09:10:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension\",\"datePublished\":\"2025-07-04T09:10:05+00:00\",\"dateModified\":\"2025-07-04T09:10:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716\"},\"wordCount\":216,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0412.webp\",\"keywords\":[\"Merck Sharp & Dohme\",\"MSD\",\"NYSE: MRK\",\"Priority reviews\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36716#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36716\",\"name\":\"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0412.webp\",\"datePublished\":\"2025-07-04T09:10:05+00:00\",\"dateModified\":\"2025-07-04T09:10:06+00:00\",\"description\":\"US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36716\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0412.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0412.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36716#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension - Insight, China's Pharmaceutical Industry","description":"US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36716","og_locale":"en_US","og_type":"article","og_title":"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension","og_description":"US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.","og_url":"https:\/\/flcube.com\/?p=36716","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T09:10:05+00:00","article_modified_time":"2025-07-04T09:10:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36716#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36716"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension","datePublished":"2025-07-04T09:10:05+00:00","dateModified":"2025-07-04T09:10:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36716"},"wordCount":216,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36716#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp","keywords":["Merck Sharp & Dohme","MSD","NYSE: MRK","Priority reviews","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36716#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36716","url":"https:\/\/flcube.com\/?p=36716","name":"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36716#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36716#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp","datePublished":"2025-07-04T09:10:05+00:00","dateModified":"2025-07-04T09:10:06+00:00","description":"US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted its market filing for Winrevair (sotatercept) for priority review. Winrevair, an activin signaling inhibitor, was initially approved in 2024 for treating adult pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capacity, enhance WHO functional class (FC), and reduce the risk of clinical worsening events.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36716#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36716"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36716#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp","width":1080,"height":608,"caption":"MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36716#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0412.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36716"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36716\/revisions"}],"predecessor-version":[{"id":36718,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36716\/revisions\/36718"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36717"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}